文献速递乳腺癌放疗放疗物理与技术

单次大分割高梯度部分乳腺照射治疗早期激素阳性乳腺癌的2期临床试验长期结果

Long-Term Results of a Phase 2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone-Positive Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-09-03

这项单中心单臂2期前瞻性试验纳入50例≥50岁绝经后早期激素阳性乳腺癌患者,在保乳术后接受单次15–22 Gy高梯度部分乳腺照射(BreaStBRT),中位随访78个月。5年同侧乳腺肿瘤复发率4%、无乳房切除生存率98%、总生存率92%,急性和晚期毒性分别为44%和68%,无急性3级及以上毒性,仅1例晚期3级纤维化,超过90%的患者和医生评价美容效果良好至优秀,生活质量稳定。

要点

  • 单次15–22 Gy高梯度部分乳腺照射的5年同侧复发率为4%。
  • 无急性3级及以上毒性,晚期仅1例3级纤维化。
  • 超过90%患者和医生评价5年美容效果良好至优秀。

核心结论

  • BreaStBRT在严格选择的早期激素阳性乳腺癌患者中显示出有前景的肿瘤学结局、良好的长期美容效果和生活质量,治疗相关毒性低。

研究设计与样本

  • 单中心、单臂、2期前瞻性临床试验,纳入50例≥50岁绝经后早期激素阳性乳腺癌患者,保乳术后接受单次高梯度部分乳腺照射。
  • 处方剂量为手术床15–22 Gy,向手术床外1 cm等距扩展区域最低剂量陡降至5 Gy,多数患者接受磁共振引导放疗。

主要发现

  • 中位随访78个月,急性放疗相关毒性发生率44%,晚期毒性发生率68%。
  • 无急性3级及以上毒性,观察到1例晚期3级纤维化。
  • 5年同侧乳腺肿瘤复发率4%,无乳房切除生存率98%,总生存率92%。
  • 随访至5年时,超过90%的病例被患者和医生评价为美容效果良好至优秀。
  • 生活质量评估显示总体健康状况、躯体功能、性功能和身体形象在随访期间保持稳定。

关键数值与推荐

  • 单次照射剂量为手术床15–22 Gy,手术床外1 cm等距扩展区域最低剂量5 Gy。
  • 主要终点包括急性和晚期毒性以及5年同侧乳腺肿瘤复发率。
  • 次要终点包括区域淋巴结复发、远处转移、无乳房切除生存率、总生存率以及患者报告的美容效果和生活质量。

临床怎么用

  • 对于经过严格选择的早期激素阳性乳腺癌患者,单次高梯度部分乳腺照射可作为术后治疗的便捷替代方案。
  • 该方案需在具备磁共振引导放疗条件的中心开展,并关注晚期毒性和美容效果。

局限性

  • 单中心、单臂、2期试验,样本量50例,缺乏对照组。
  • 需要进一步开展对比试验以巩固BreaStBRT在临床实践中的地位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study evaluates the long-term outcomes of single-fraction, high-gradient partial breast irradiation (BreaStBRT) as a postoperative treatment in patients with early-stage, hormone-positive breast cancer. It aims to assess acute and late treatment-related toxicity, cosmesis, patient-reported quality of life (QoL), and oncologic outcomes. METHODS AND MATERIALS: This single-institution, single-arm, phase 2 prospective trial included postmenopausal women ≥50 years with early-stage, hormone-positive breast cancer treated with breast-conserving therapy followed by BreaStBRT. Patients were treated in a single-fraction with a high-gradient by delivering a dose of 15 to 22 Gy to the surgical bed with a steep fall-off to a minimum of 5 Gy to a 1 cm isometric expansion from the surgical bed; most patients were treated with magnetic resonance imaging-guided radiation therapy. Primary endpoints included acute and late toxicity and 5-year ipsilateral breast tumor recurrence. Secondary endpoints included regional-nodal recurrence, distant metastasis, mastectomy-free survival, and overall survival, along with patient-reported cosmesis and QoL assessments. RESULTS: Fifty patients were treated between 2015 and 2018. Median follow-up was 78 months. Acute and late radiation-related toxicities were observed in 44% and 68% of patients, respectively; no acute grade 3 or higher toxicities were reported, and one instance of late grade 3 fibrosis was observed. Five-year ipsilateral breast tumor recurrence, mastectomy-free survival, and overall survival were 4%, 98%, and 92%, respectively. Cosmesis was rated as good to excellent in over 90% of cases by both patients and physicians through a 5-year follow-up. QoL assessments showed stable global health, physical functioning, sexual functioning, and body image results through follow-up. CONCLUSIONS: BreaStBRT provides promising oncologic outcomes and favorable long-term cosmesis and QoL results with a low rate of treatment-related toxicity. This convenient regimen offers a viable alternative for carefully-selected early-stage, hormone-positive breast cancer patients. Further comparative trials are warranted to solidify the role of BreaStBRT in clinical practice.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lakomy DS, Kennedy WR, Laugeman E, et al. Long-Term Results of a Phase 2 Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40912507. doi:10.1016/j.ijrobp.2025.07.1410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。